FDA approves new COVID-19 antibody dr... - LUpus Patients Un...

LUpus Patients Understanding and Support

3,216 members1,045 posts

FDA approves new COVID-19 antibody drug to protect most vulnerable from coronavirus

lupus-support1 profile image

FDA approves new COVID-19 antibody drug to protect most vulnerable from coronavirus

AstraZeneca’s Evusheld okayed for those 12 and older who didn’t respond adequately to vaccines or who have history of severe allergic reactions to shots

WASHINGTON — Federal health officials on Wednesday authorized a new COVID-19 antibody drug for people with serious health problems or allergies who can’t get adequate protection from vaccination.

Antibody drugs have been a standard treatment for treating COVID-19 infections for over a year. But the AstraZeneca antibody-drug cleared by the Food and Drug Administration is different. It’s the first intended for long-term prevention against COVID-19 infection, rather than short-term treatment.

People who could benefit from the antibody drug include cancer patients, organ transplant recipients and people taking immune-suppressing drugs for conditions like rheumatoid arthritis. Health experts estimate about 2% to 3% of the US population falls into that group.

“These people still have to shelter in place because they’re at really high risk of severe disease and death,” said Dr. David Boulware of the University of Minnesota, ahead of the announcement. “So having this therapy will enable a lot of them to get back to their normal lives.”

Specifically, the FDA authorized the AstraZeneca drug called Evusheld for adults and children 12 and older whose immune systems haven’t responded adequately to COVID-19 vaccines or who have a history of severe allergic reactions to the shots. Regulators said the required two antibody injections may be effective at preventing COVID-19 infections for six months.

Like similar drugs, AstraZeneca’s delivers laboratory-made versions of human antibody proteins, which help the immune system fight off viruses and other infections.

Evusheld combines two types of synthetic antibodies (tixagevimab and cilgavimab), and is given as two intramuscular injections, one straight after the other. These antibodies help the immune system fight off the virus by targeting its spike protein, which allows it to enter cells and infect them.

The FDA said that the treatment “may be effective for pre-exposure prevention for six months.”

It cannot be administered to someone who is already infected with the virus, the FDA said, although AstraZeneca is testing it for such treatment.

Side effects may include an allergic reaction, bleeding from the injection site, headache, and fatigue.

The FDA authorization was based on a clinical trial carried out on unvaccinated people over 59 years of age, or with a chronic disease, or at high risk of infection.

The drug was given to 3,500 people while 1,700 received a placebo. The trial showed that the treatment cut the risk of developing Covid-19 by 77 percent.

In this image from undated video provided by AstraZeneca in December 2021, a worker packages the company’s Evusheld medication. (AstraZeneca via AP)

The FDA and other health authorities have stressed that antibody drugs are not a substitute for vaccines, which offer the most effective, long-lasting and economical form of virus protection. Antibody drugs are tricky to manufacture and often cost more than $1,000 per dose, compared with vaccines that are typically under $30 per shot.

The FDA has authorized three other antibody therapies from Regeneron, Eli Lilly and GlaxoSmithKline, with the US government purchasing hundreds of thousands of doses. All require an IV or injection. They are used to treat people with recent infections who have the highest risk of progressing to severe COVID-19 because of other health issues. Two can be used to prevent infection after a possible coronavirus exposure.

AstraZeneca’s drug would be used differently— only as a long-term preventive measure in people who have increased vulnerability to the virus.

In a company study, people who received Evusheld had a 77% lower risk of infection than people who received a dummy shot over six months, the FDA said.

SOURCE: timesofisrael.com/fda-appro...

LUpus Patients Understanding & Support (LUPUS): lupus-support.org/topic/341...